Bio Plus Co

Bio Plus Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 181.06. In the previous year, Cash Conversion Cycle (CCC) was 230.96 — a change of -21.61% (lower).

Cash Conversion Cycle

181.06

YoY

-21.61%

Last updated:

Cash Conversion Cycle (CCC) of Bio Plus Co is 2025 181.06 . Cash Conversion Cycle (CCC) of Bio Plus Co was 2024 230.96 . It decreases by -21.61% lower compared to the previous year.

The Bio Plus Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
259.56 KRW
Jan 1, 2019
317.07 KRW
Jan 1, 2020
253.18 KRW
Jan 1, 2021
173.62 KRW
Jan 1, 2022
226.87 KRW
Jan 1, 2023
226.60 KRW
Jan 1, 2024
230.96 KRW
Jan 1, 2025
181.06 KRW
The Bio Plus Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
181.06-21.61%
230.96+1.92%
226.60-0.12%
226.87+30.67%
173.62-31.43%
253.18-20.15%
317.07+22.16%
259.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Cash Conversion Cycle (CCC) of Bio Plus Co is 181.06 in 2025.

Cash Conversion Cycle (CCC) of Bio Plus Co changed from 230.96 to 181.06, representing a -21.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio Plus Co

All Key Metrics — Bio Plus Co